Keenova Therapeutics

Specialty pharma -- reorganizing post-Chapter-11 (targeting a 2026 NYSE relisting as "Keenova"), ticker deliberately left null given the transitional OTC listing

Privately held: no public share price · Ireland

Assets

(4 total)
4Total Assets
4Approved
0Phase 3 / Filed
0Phase 1–2 / Early
11Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Approved
5-HT1B/1D receptorSmall molecule
Migraine
nitric oxide(INOmax)
Approved
Nitric oxideOther
Persistent Pulmonary Hypertension of the Newborn
Approved
Melanocortin receptors (primarily MC2R on the adrenal cortex) · Melanocortin 2 receptor (MC2R) (agonist)Peptide
Psoriatic ArthritisSystemic Lupus ErythematosusRheumatoid ArthritisMultiple SclerosisEpilepsyDermatomyositisNon-Infectious UveitisIdiopathic Inflammatory MyopathiesLupus Nephritis
Multiple Sclerosis Exacerbations
Approved
5-HT1B/1D receptorSmall molecule
Migraine

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q3$753M$44M$1.0B$291Mreport ↗

Mallinckrodt reported third-quarter 2025 net sales of $753.1M, up 49.0% YoY, with R&D spend of $44.3M and cash and equivalents of $1,047.9M. The company reported a net loss of $291.1M for the quarter, versus a net loss of $26.2M in the prior-year period, and adjusted EBITDA of $111.3M.

Management guided fourth-quarter 2025 Keenova net sales of $485M to $505M and adjusted EBITDA of $155M to $165M, while raising full-year Acthar Gel net sales growth guidance to 30% to 35%. The company completed its merger with Endo on July 31, 2025, initiated a XIAFLEX clinical program for hammertoe with over 30 patients recruited, and completed the spin-off of its generics and sterile injectables businesses as Par Health, with the branded therapeutics business now operating as Keenova Therapeutics.

Annual history (1 year)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$1.4B—$813M$490Mreport ↗